



Mechanisms of Congenital Heart Disease Caused by NAA15 Haploinsufficiency

Tarsha Ward, Warren Tai, Sarah Morton , Francis Impens, Petra Van Damme, Delphi Van Haver , Evy Timmerman, Gabriela Venturini , Kehan Zhang , Min Young Jang, Jon A.L. Willcox , Alireza Haghghi , Bruce D. Gelb, Wendy K. Chung , Elizabeth Goldmuntz, George A. Porter, Jr, Richard P. Lifton, Martina Brueckner, H. Joseph Yost, Benoit G. Bruneau, Joshua Gorham, Yuri Kim , Alexandre Pereira, Jason Homsy, Craig C. Benson, Steven R. DePalma , Sylvia Varland , Christopher S. Chen, Thomas Arnesen , Kris Gevaert*, Christine Seidman , J.G. Seidman

RATIONALE: NAA15 (N-alpha-acetyltransferase 15) is a component of the NatA (N-terminal acetyltransferase complex). The mechanism by which NAA15 haploinsufficiency causes congenital heart disease remains unknown. To better understand molecular processes by which NAA15 haploinsufficiency perturbs cardiac development, we introduced *NAA15* variants into human induced pluripotent stem cells (iPSCs) and assessed the consequences of these mutations on RNA and protein expression.

OBJECTIVE: We aim to understand the role of NAA15 haploinsufficiency in cardiac development by investigating proteomic effects on NatA complex activity and identifying proteins dependent upon a full amount of NAA15.

METHODS AND RESULTS: We introduced heterozygous loss of function, compound heterozygous, and missense residues (R276W) in iPSCs using CRISPR/Cas9. Haploinsufficient *NAA15* iPSCs differentiate into cardiomyocytes, unlike *NAA15*-null iPSCs, presumably due to altered composition of NatA. Mass spectrometry analyses reveal $\approx 80\%$ of identified iPSC NatA targeted proteins displayed partial or complete N-terminal acetylation. Between null and haploinsufficient *NAA15* cells, N-terminal acetylation levels of 32 and 9 NatA-specific targeted proteins were reduced, respectively. Similar acetylation loss in few proteins occurred in *NAA15* R276W induced pluripotent stem cells. In addition, steady-state protein levels of 562 proteins were altered in both null and haploinsufficient *NAA15* cells; 18 were ribosomal-associated proteins. At least 4 proteins were encoded by genes known to cause autosomal dominant congenital heart disease.

CONCLUSIONS: These studies define a set of human proteins that requires a full NAA15 complement for normal synthesis and development. A 50% reduction in the amount of NAA15 alters levels of at least 562 proteins and N-terminal acetylation of only 9 proteins. One or more modulated proteins are likely responsible for NAA15-haploinsufficiency mediated congenital heart disease. Additionally, genetically engineered induced pluripotent stem cells provide a platform for evaluating the consequences of amino acid sequence variants of unknown significance on NAA15 function.

GRAPHIC ABSTRACT: A [graphic abstract](#) is available for this article.

Key Words: congenital heart defects ■ haploinsufficiency ■ induced pluripotent stem cells ■ proteins ■ proteomics ■ ribosomes

Editorial, see p 1170 | In This Issue, see p 1119 | Meet the First Author, see p 1120

Congenital heart disease (CHD), which affects about 1% of newborns, reflects defects in the developmental program of the heart.^{1,2} Defining the genetic

causes of CHD will provide new insights into mechanisms of cardiac development that may eventually benefit patients with CHD and their families. Whole exome

Correspondence to: Jonathan G. Seidman, PhD, New Research Bldg Room 256, 77 Ave Louis Pasteur, Boston, MA 02115. Email seidman@genetics.med.harvard.edu
*K. Gevaert, C. Seidman, and J.G. Seidman contributed equally.

The Data Supplement is available with this article at <https://www.ahajournals.org/doi/suppl/10.1161/CIRCRESAHA.120.316966>.

For Sources of Funding and Disclosures, see page 1167.

© 2021 The Authors. *Circulation Research* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Circulation Research is available at www.ahajournals.org/journal/res

Novelty and Significance

What Is Known?

- NAA15 (N-alpha-acetyltransferase 15) is an 866 amino acid subunit of the NatA (N-terminal acetyltransferase), which acetylates the N-terminal residue of many eukaryotic proteins.
- Patients with congenital heart disease (CHD) have genetic variants in the NAA15 gene predicted to be harmful, yet there is limited knowledge of how NAA15 variants cause CHD.
- Human induced pluripotent stem cells (iPSCs) can be used as a human model to study biological consequences of genetic variants that may cause disease.

What New Information Does This Article Contribute?

- Exome sequence analysis of 4511 patients with CHD identified 20 subjects with rare inherited or de novo variants predicted to perturb NAA15, which may be responsible for their condition.
- NAA15 haploinsufficiency in iPSCs has little effect on the transcriptome. However, a 50% reduction of NAA15 protein does lead to impaired cardiomyocyte contractility and proteome integrity.
- Expression levels of ribosome-associated proteins and 4 proteins that encode genes known to cause autosomal dominant CHD are altered in NAA15 haploinsufficient and deficient iPSCs.

CHD, which affects about 1% of newborns, reflects defects in heart development during fetal life. Defining genetic causes of CHD provides new insights into mechanisms of cardiac development that may eventually benefit patients with CHD and their families. We have used induced pluripotent stem cells to model NAA15 haploinsufficiency. In iPSCs, NAA15 haploinsufficiency and deficiency cause loss of N-terminal acetylation of 9 and 32 proteins. In addition, we discovered 562 proteins with altered expression levels; 18 proteins are ribosome-associated. Among affected proteins, 4 proteins are known CHD genes and are likely candidates that require a full complement of NAA15. We conclude that patients with CHD with NAA15 haploinsufficiency likely have altered ribosomal activity, which effects steady-state levels of proteins essential for early cardiac development. Genetically engineered iPSCs can be used as a platform for defining the potential pathogenicity of NAA15 variants of unknown significance.

Nonstandard Abbreviations and Acronyms

CHD	congenital heart disease
GFP	green fluorescent protein
iPSC	induced pluripotent stem cells
iPSC-CMs	induced pluripotent stem cell-derived cardiomyocytes
LoF	loss of function
NAT	N-terminal acetyltransferase
Nt	N-terminal

sequencing of CHD probands and their parents have enabled the identification of recurrent damaging variants in multiple genes that likely are critical for normal cardiac development.³ Functional studies are necessary to further define these gene functions and the pathogenetic mechanisms of damaging variants. While loss of function (LoF) variants infer that haploinsufficiency of the encoded protein contributes to CHD, the consequence of missense variants on protein function are less readily interpreted, often leading to classification of these as variants of unknown significance although some may contribute to the CHD.²

We previously reported 2 patients with CHD with de novo heterozygous LoF variants in *NAA15* (N-alpha-acetyltransferase 15), which encodes a protein subunit of the NAT (N-terminal [Nt] acetyltransferase) complex.²⁻⁴ In addition to CHD, these patients had extra-cardiac disorders including neurodevelopmental deficits.^{2,3} Prior studies have reported damaging *NAA15* variants in patients with other congenital malformations and neurodevelopmental abnormalities.⁵⁻⁷

Acetylation of the N-terminus of proteins is a prevalent modification that occurs in $\approx 85\%$ of yeast and human proteins.^{8,9} The effect of Nt-acetylation on proteins is diverse and includes changes to protein stability, complex formation, protein folding, and aggregation.¹⁰ The NatA complex, one of 8 NAT types, is essential in most, if not all, eukaryotes and is responsible for the majority of Nt-acetylation.^{10,11} This complex binds the ribosome and was shown to acetylate nascent polypeptide chains at specific Nt amino acids (Ser-, Thr-, Ala-, Val-, Gly-, and Cys-) after the initiating methionine is removed.^{8,10,12,13} The NatA complex is formed by the catalytic subunit NAA10 and the auxiliary unit NAA15. HYPK (Huntingtin interacting protein K) is a chaperone protein that attaches to the NatA complex along with subunit NAA50.¹⁴⁻¹⁷ NAA50 also forms part of the NatE complex, which displays a distinct substrate

specificity compared with NatA.^{10,18} NAA15 is a subunit of both the NatA and NatE complexes, and its role is to position the catalytic subunits in close vicinity to the nascent polypeptides; in the case of NAA10, it also modulates its substrate specificity.^{10,19–21} Additionally, NAA15 interaction with NAA10 and HYPK has been implicated in regulation of protein folding and Nt-acetylation fidelity.^{15,22} Abnormal NatA complex function has been previously associated with human cancers and neurological disorders.^{5,23,24} To date, the relationship between Nt-acetylation, NAA15, and CHD has not been investigated.

We studied human isogenic induced pluripotent stem cell (iPSC) lines that were engineered to contain *NAA15* variants identified in patients with CHD and predicted to be damaging. We evaluated whether iPSCs with *NAA15* variants differentiated into cardiomyocytes. By assessing both Nt-acetylation and protein levels by mass spectrometry (MS), we demonstrate that *NAA15* haploinsufficiency perturbs normal function of undifferentiated iPSCs. We identify proteins that require the full complement of *NAA15* to preserve the integrity of these stem cells for cardiac development.

METHODS

Data Availability

All data and materials have been made publicly available. Further details are provided in the Major Resources Table located in the [Data Supplement](#).

Study Cohort With CHD

CHD subjects ($n=4511$) were recruited to the Congenital Heart Disease Network Study of the Pediatric Cardiac Genomics Consortium (CHD GENES; URL: <https://www.clinicaltrials.gov>; Unique identifier: NCT01196182) or the DNA biorepository of the Single Ventricle Reconstruction trial after approval from Institutional Review Boards as previously described.^{1,25,26} All subjects or their parents provided informed consent. Clinical diagnoses, including cardiac and noncardiac congenital anomalies, were obtained from review of patient charts and family interview.

CRISPR Gene Editing and Mutation Confirmation

Isogenic personal genome project 1 iPSCs were modified using CRISPR/Cas9 technology to create *NAA15* LoF or missense mutation cell lines.²⁷ Further details provided in Methods in the [Data Supplement](#).

Label-Free Quantitative Shotgun Proteomics and Data Analysis

Two independent iPSC lines of both wild type (WT) cells and *NAA15* mutant cells were grown in 10 cm petri dishes until near confluency. iPSCs were detached and using Accutase (Millipore) and collected in 15 cm centrifuge tubes. Cells were centrifuged (Beckman) in a 15 mL tube at 1000 rpm for 5

minutes. Cells were washed with PBS and pelleted by centrifugation. Eight samples of each genotype were collected, and a total of 24 samples were prepared for LC-MS/MS analysis. Further details provided in Methods in the [Data Supplement](#).

The MS proteomics data have been deposited to the ProteomeXchange Consortium (<http://proteomecentral.proteomexchange.org>) via the PRIDE partner repository with the data set identifiers PXD017672 and PXD018013.

Bioinformatic Analysis and Gene Ontology Analysis

Gene ontology annotation proteome was derived using the R package clusterProfiler.²⁸ Proteins were classified by Gene ontology annotation based on biological process, molecular function, and cellular component. Quantified proteins detected by MS of iPSCs were used as a background and other parameters with default. The *P* values were adjusted by Bonferroni correction for multiple testing.

Statistics

Single comparisons were analyzed by using the Student *t* test, with significance defined as $P<0.05$. Multiple comparisons between genotypes were analyzed using 1-way ANOVA with post hoc Tukey HSD, with significance defined as $P<0.05$. For proteomics, pairwise SAM *t* tests (or pairwise statistical testing using the SAM method²⁹) were performed and significant hits determined using as cutoff values a permutation based false discovery rate (FDR) of 0.01 (1000 permutations) and a background variance parameter s_0 of 1. For all experiments analyzed for statistical significance, only within-test corrections were made.

RESULTS

NAA15 Variants Are Associated With CHD and Other Extra Cardiac Anomalies

Whole exome sequencing of 4511 patients with CHD^{1,24} identified 4 subjects with a rare LoF variant (allele frequency <0.00005) in the *NAA15* gene, resulting in *NAA15* haploinsufficiency (Figure 1A). Parental analyses indicated that 3 of these LoF variants (p.Ser761*, p.Lys336Lys fs*6, and p.Arg470*) arose de novo in the probands.²⁴ The inheritance of the p.Ala718fs variant is uncertain, as parental samples were unavailable. Among $\approx 125\,000$ subjects in the gnomAD database,¹² 14 *NAA15* LoF variants are reported, inferring an 8.9-fold higher frequency of *NAA15* LoF variants in CHD probands ($P=0.002$).

The CHD phenotypes included tetralogy of Fallot, heterotaxy with d-looped ventricles, transposition of the great arteries, and hypoplastic left or right heart syndrome (Figure 1C and Table I in the [Data Supplement](#)). In addition to cardiac anomalies, all 4 patients with CHD with a *NAA15* LoF variant had extracardiac anomalies including seizures, neurobehavioral, ophthalmologic, auditory, or orthopedic disorders (Figure 1C and Table I in the [Data Supplement](#)).⁵




Figure 1. NAA15 variants discovered in patients with congenital heart disease patients.

A, Schematic diagram of the *NAA15* (N-alpha-acetyltransferase 15) gene. The *NAA15* gene consists of tetracoordinate repeats (blue) essential for interaction with the NatA (N-terminal acetyltransferase) complex subunit NAA10 and a HYPK (Huntingtin interacting protein K) interacting domain at the C terminus. Location of variants identified in patients with congenital heart disease (CHD); loss of function [LoF] variants are underlined and CRISPR/Cas9-derived variants in induced pluripotent stem cell (iPSCs; magenta) are shown. **B**, The subunit composition of NatA and NatE complexes. NAA15 is the auxiliary unit for both complexes. **C**, Table of cardiovascular and neuronal clinical phenotypes of patients with CHD. *indicates LoF variants.

We also identified 15 very rare (allele frequency $<1.0 \times 10^{-5}$ or absent from the gnomAD database¹²) inherited *NAA15* missense variants among these 4511 patients with CHD (Figure 1A and Table I in the [Data Supplement](#)). In addition, one missense variant, R276W (Figure 1A and Figure IA and IB in the [Data Supplement](#)), could not be assessed for inheritance. The frequency of rare missense alleles in the Pediatric Cardiac Genomics Consortium (PCGC) cohort was 0.0035 ($n=16$ of 4511 CHD probands), significantly higher than the frequency observed among $\approx 115\,000$ Gnomad subjects (frequency, 0.002; $n=198$; $P=0.02$; odds ratio, 1.8). CHD probands with rare *NAA15* missense variants had notably fewer extracardiac anomalies than CHD probands with *NAA15* LoF variants (Table I in the [Data Supplement](#)). Hence, despite the observation that these very rare *NAA15* missense variants were transmitted from an unaffected parent, we suspected that some of them contribute to CHD.

Genetically Engineered iPSCs Model NAA15 Haploinsufficiency

We introduced *NAA15* variants into the iPSC line, personal genome project 1, using CRISPR/Cas9 gene editing (see Methods in the [Data Supplement](#)) to create human iPSCs with reduced or no NAA15 protein. Two

independent cell lines were constructed with each genotype *NAA15*^{-/-}, *NAA15*^{+/-}, and *NAA15*^{+R276W} (Figure 1A, Figure 1A through 1C and Table II in the [Data Supplement](#)) and studied as detailed below. *NAA15* variants in iPSCs were confirmed both by Sanger sequencing and next generation sequencing of PCR amplified products (Figure 1IA through 1IC in the [Data Supplement](#)).

RNA expression levels for each of the 2 independent iPSC lines in *NAA15*^{+/+} and *NAA15*-mutant iPSCs, were first characterized by RNAseq. *NAA15* mRNA levels were reduced by 56% and 24% in the *NAA15*^{+/-} and *NAA15*^{+R276W} iPSCs, respectively (Figure 2A and Table III in the [Data Supplement](#)). There was a 99% decrease in *NAA15* mRNA in *NAA15*^{-/-} iPSCs, suggesting that these variants triggered nonsense-mediated decay (Figure 2A). We performed MS-based shotgun proteomics in at least 3 replicates for each of the 2 independent lines. NAA15 protein was near-normal levels in *NAA15*^{+/-} iPSCs but absent from *NAA15*^{-/-} iPSCs (Figure 2B). The amount of NAA15 protein detected by MS in *NAA15*^{+/-} iPSCs could represent a proportion of truncated NAA15 polypeptides. To confirm this hypothesis, NAA15 protein levels were measured in 2 independent biological replicates of both WT and *NAA15* mutant iPSCs by Western blotting (Figure IID and IIE in the [Data Supplement](#)), which supported this conclusion. NAA15 protein was reduced




Figure 2. *NAA15*^{-/-} and *NAA15*^{+/-R276W} induced pluripotent stem cells (iPSCs) develop into cardiomyocytes, while *NAA15* (N-alpha-acetyltransferase 15) null iPSCs have reduced viability.

A, Graph shows RNA expression of the NatA (N-terminal acetyltransferase) components in *NAA15*-mutant iPSCs. *NAA15* RNA levels are significantly lowered in iPS cells with *NAA15*^{+/-} and *NAA15*^{-/-} variants compared with wildtype iPSCs. Data was collected from 2 independent cell lines for each genotype and as technical replicates for selected lines. Total cell lines analyzed: *NAA15*^{+/+} (n=3), *NAA15*^{-/-} (n=4), *NAA15*^{+/-} (n=4), and *NAA15*^{+/-R276W} (n=2). Significance of differences between *NAA15* mutant iPSCs and wildtype iPSCs were evaluated by Student *t* tests, $P < 0.05$ (*P* values were adjusted by Bonferroni correction; only significant adjusted *P* values are displayed). All data points are presented and plotted as mean \pm SEM. **B**, Graph represents fold change ratios of relative protein levels in *NAA15* mutant iPSCs compared with wildtype iPSCs for Nat complex subunits. Relative protein abundance was quantified by MaxLFQ algorithms integrated in the MaxQuant software. Data was collected from two independent undifferentiated iPS cell lines for each *NAA15* mutant genotype and as technical replicates for each cell line. Total cell lines analyzed: *NAA15*^{+/-} (n=8), *NAA15*^{-/-} (n=8), *NAA15*^{+/-} (n=7), and *NAA15*^{+/-R276W} (n=8). Significant changes indicated by *P* values were calculated using pairwise comparison SAM *t* test method and a permutation based false discovery rate (FDR) of 0.01 (1000 permutations) as cutoff values with a background variance parameter *s*₀ of 1. All data points are presented and plotted as mean \pm SEM. **C**, Representative images of *NAA15*^{+/+} iPSCs and *NAA15*^{-/-} iPSCs stained with cardiac troponin T antibody (green), α -actinin (magenta), and DAPI for nuclei (blue). A representative image for each cell type is presented. Normal sarcomeres were observed in both *NAA15* mutant and wildtype iPSC-CMs. Magnification, 60 \times ; scale bar 25 μ m.

in *NAA15*^{+/-} iPSCs by about 50%, and full length *NAA15* protein was not detectable in *NAA15*^{-/-} iPSCs (Figure IID and IIE in the [Data Supplement](#)).

Because *NAA15* is normally associated with components *NAA10*, *HYPK*, and *NAA50*^{15,17,18} (Figure 1B), we assessed the levels of these proteins in the mutant iPSCs using MS. Both *NAA15*^{-/-} and *NAA15*^{+/-} iPSCs showed decreased protein levels of *NAA10* (Figure 2B). *NAA50*, the catalytic unit of NatE and binding partner of *NAA15* protein, was reduced in *NAA15*^{-/-} iPSCs. Significant reduction of the *NAA50* protein did not occur in *NAA15*^{+/-} iPSCs (Figure 2B). Noticeably, *HYPK*, a *NAA15* binding partner and subunit of the NatA complex was significantly reduced in both *NAA15*^{+/-} and *NAA15*^{-/-} iPSCs (Figure 2B).

We further explored the functional effects of *NAA15*^{+/-} and *NAA15*^{+/-R276W} using a yeast assay in which the hNatA

(human NatA complex) functionally replaced yeast NatA, as shown by complementation of growth phenotypes with partial rescue of the NatA-specific Nt-acetylome.⁸ HsNatA D335fs and S761* failed to rescue the temperature-sensitive growth phenotype of yNatA Δ (Figure IIIA through IIIC in the [Data Supplement](#)), suggesting that *NAA15*^{+/-} results in impaired NatA functionality. However, in this yeast assay, human HsNatA R276W rescued yeast growth suggesting at least partial NatA function in yeast (Figure IIIC in the [Data Supplement](#)). Noticeably, *Schizosaccharomyces pombe* *NAA15* has a tryptophan residue at position 276 while all mammals have an arginine residue, which suggests that this residue is functionally important in human cells. As such, we suggest that rescue of yeast growth experiments might not fully provide functional assessments of mutant human *NAA15* proteins.

NAA15^{+/-} and NAA15^{+R276W} iPSCs Develop Into Contractile Cardiomyocytes, While NAA15^{-/-} iPSCs Have Reduced Viability

To test whether *NAA15* variants have an effect on iPSC maturation, 2 independent iPSC lines for each genotype (*NAA15*^{-/-}, *NAA15*^{+/-}, and *NAA15*^{+R276W}) were differentiated into cardiomyocytes using a 13-day differentiation protocol to assess for the development and contractility of sarcomeres.^{30,31} Both *NAA15*^{+/-} and *NAA15*^{+R276W} cells differentiated into cardiomyocytes (Figure 2C, a and b), however, *NAA15*^{-/-} iPSCs grew slowly (data not shown) and failed to differentiate. Cell viability of *NAA15*-mutant iPSCs was assessed (see Methods in the [Data Supplement](#)). Similar to observations reported in *NAA15*/NatA yeast knockout and human knockdown cells,^{19,23,32–34} *NAA15*^{-/-} iPSCs had significantly retarded growth and cell death ($P=0.001$; average cell death is 12% in *NAA15*^{+/+} iPSCs versus 32% in *NAA15*^{-/-} iPSCs, $n=2$). *NAA15*^{+/-} iPSC-derived cardiomyocytes (iPSC-CMs) were stained with cardiac troponin T and actinin antibodies to visualize sarcomere structures (Figure 2C, a and b). *NAA15* mutant cell sarcomeres were indistinguishable from WT cell sarcomeres (Figure 2C, a and b and Figure IV and Table IV in the [Data Supplement](#)).

Contractility of *NAA15*^{+/-} and *NAA15*^{+R276W} iPSC-CMs was monitored by live image analysis (Movies I and II in the [Data Supplement](#)). Two biological replicates of *NAA15* mutant iPSC-CMs and one of 2 biological replicates for WT iPSC-CMs were incubated with GFP (green fluorescent protein)-actinin lentivirus to enable high fidelity tracking of sarcomere function³⁵ (Movies III through V in the [Data Supplement](#)). The lengths of GFP-labeled sarcomeres were measured during the contractile cycle. Contractile measurements of unloaded (ie, sarcomeres that were not working against resistance) demonstrated no difference in rates of sarcomere shortening or contraction between mutant and WT cells (Figure VA in the [Data Supplement](#)). To better recapitulate native cardiomyocyte architecture and mechanics, the function of loaded sarcomeres from these cells grown as 3-dimensional micro-tissue structures,^{36,37} where sarcomeres work against resistance, were created from WT iPSC-CMs and 2 biological replicates of *NAA15* mutant iPSC-CMs (Movies VI through VIII in the [Data Supplement](#)). In contrast to unloaded 2-dimensional tissue sarcomere function, image analysis show loaded *NAA15*^{+/-} iPSC-CM sarcomeres exhibited a smaller percent contraction than WT iPSC-CM sarcomeres (Figure VB in the [Data Supplement](#)).

Nt-acetylation in NAA15 Haploinsufficient, Null, and R276W Missense iPSCs

We studied Nt-acetylation of 2 biological replicates in iPSCs with *NAA15* variants and WT using a MS-based Nt enrichment assay.^{8,38–40} NatA acetylates N-termini containing Ser-, Thr-, Ala-, Val-, Gly-, or Cys.^{10,12} We

identified a total of 989 previously annotated N-termini⁴¹ in one or both of the 2 independent cell lines for WT and *NAA15* mutant iPSCs (Table V in the [Data Supplement](#)); ≈ 650 N-termini peptides were identified in each cell line (Tables V and VI in the [Data Supplement](#)). NatA targeted sequences represented $\approx 60\%$ of the 989 detected N-termini peptides (Tables V and VI in the [Data Supplement](#)); no Cys-starting peptides were detected. In *NAA15*^{+/+} iPSCs, we observed 17 Nt peptides that were partially acetylated (10%–95%) and 359 with complete ($>95\%$) Nt-acetylation (Figure 3A and Tables V and VI in the [Data Supplement](#)). Of the completely or partially Nt-acetylated peptides,^{8,10} 98% have an alanine, threonine, or serine at position 2 (Figure 3B and Tables VI and VII in the [Data Supplement](#)). However, peptides with partial acetylation have a much higher fraction of Nt glycine or valine residues (Figure 3C and Tables VI and VII in the [Data Supplement](#)). The preference for acetylation of proteins with Nt alanine and serine residues was preserved in *NAA15*-mutant iPSCs as observed in previous studies (Tables VI and VII in the [Data Supplement](#)).²³

Protein Nt-acetylation in *NAA15* mutant iPSCs was compared with Nt-acetylation in WT iPSCs. Only a limited number of putative NatA-type N-termini substrates had $>10\%$ difference in acetylation between wild type and mutant iPSCs (Figure 3, Table 1, and Figure VI in the [Data Supplement](#)). In *NAA15*^{-/-} iPSCs 32 proteins showed these changes (Figure 3B through 3D and Table 1). Notably, all proteins that had partial acetylation in WT iPSCs lacked Nt-acetylation in *NAA15*^{-/-}. Nine of these proteins were altered in *NAA15*^{+/-} iPSCs and 8 had altered Nt-acetylation in *NAA15*^{+R276W} iPSCs (Figure 3E and 3F, Table 1).

All proteins with reduced acetylation in mutant iPSCs displayed NatA-type substrate specificity (Tables 1 and 2, Table V in the [Data Supplement](#)). Greater than 50% of proteins with altered Nt-acetylation had an alanine residue at position 2 and $>30\%$ also had an alanine residue at position 3 (Table 2).²³ The distribution of N-terminal residues in proteins with altered Nt-acetylation did not differ significantly from the distribution of N-terminal residues in proteins with unchanged N-terminal acetylation in these cells (not shown). We deduced that *NAA15* variants or deficiency altered N-terminal acetylation in a small number of NatA substrate proteins and with no preference for an extended N-terminal amino acid substrate specificity.

We noticed that some proteins reduced in Nt-acetylation (Figure 3D) have functions in cellular proliferation and survival,^{42–46} perhaps accounting for the deficits in growth and viability of *NAA15*^{-/-} iPSC.^{41–46} To understand whether the change in Nt-acetylation status compromised the function of these proteins and contributed to the phenotype of *NAA15*^{-/-} iPSCs, we used a combination of shotgun MS-based proteomics and pairwise comparison by SAM *t* test (FDR=0.01; Tables VIII through X in the [Data Supplement](#)). Nine proteins with reduced acetylation correlated with changes in protein expression in *NAA15*^{-/-} iPSCs




Figure 3. N-terminal acetylation in *NAA15*^{+/-} and *NAA15*^{-/-} induced pluripotent stem cells (iPSCs).

A, N-terminal peptides acetylated in *NAA15*^{+/-} iPSCs are categorized by NAT-type substrate specificity. NatA (N-terminal acetyltransferase) targets are displayed according to percent Nt-acetylation; Nt-acetylation >10% highlighted in gold and Nt-acetylation <10% highlighted in light gold. **B** and **C**, The number of Nt-acetylated NatA-type N-terminal peptides represented by residues A, G, S, T, or V in *NAA15* mutant and wildtype iPSCs. Data is displayed as the absolute number of peptides measured from the sum of 2 biological replicates for each genotype. Alanine and serine residues are preferentially acetylated in peptides with >10% Nt-acetylation; glycine and valine residues are representative of N-termini with <10% Nt-acetylation. Primary peptide summary provided in Table V in the [Data Supplement](#). There were no statistically significant differences between genotypes (hypergeometric test; data not shown). **D–F**, Representative scatter plots display the correlation of the degrees of Nt-acetylation of all N-termini identified as NatA targets in *NAA15*^{-/-}, *NAA15*^{+/-}, *NAA15*^{+/-R276W}, and *NAA15*^{+/+} iPSCs. Each plot compares *NAA15* (N-alpha-acetyltransferase 15) mutant iPSCs to wildtype iPSCs. Differentially acetylated N-termini are found below the line of identity (y intercept=0, slope=1). Peptides lose acetylation moieties in *NAA15*-mutant iPSCs. *NAA15*^{-/-} iPSCs have the largest number of peptides (n=32) with reduced Nt-acetylation. There are N-termini with reduced N-terminal acetylation in *NAA15*^{+/-} iPSCs (n=9) and *NAA15*^{+/-R276W} iPSCs (n=8). Decreased protein expression changes are highlighted in red. COPS3 indicates COP9 signalosome complex subunit 3; DDX54, ATP-dependent RNA helicase; NDUFB6, NADH dehydrogenase (ubiquinone) 1 β subcomplex subunit 6; PABPN1, polyadenylate-binding protein 2; PPWD1, peptidyl-prolyl isomerase domain and WD repeat-containing protein 1; and VPS4A, vacuolar protein sorting-associated protein 4.

(Figure 3D and 4A). Among these, measurable acetylation occurred in 3 proteins in *NAA15*^{+/-} and in one protein in *NAA15*^{+/-R276W} iPSCs (Figure 3E and 3F).

Altered Protein Expression Due to *NAA15* Haploinsufficiency or Deficiency

Using shotgun proteomics, we studied 2 independent undifferentiated iPSC lines for each *NAA15* mutant

genotype and at least 3 technical replicates for each sample to assess protein levels (Table VIII in the [Data Supplement](#)). Among 5196 proteins identified by MS, extracts from *NAA15*^{+/-} iPSCs, *NAA15*^{-/-} iPSCs, and both revealed a total of 1209 proteins that were differentially expressed (pairwise comparison by *t* test) compared with WT iPSCs (Figure 4A and 4B, Figure VII and Tables VIII through X in the [Data Supplement](#)). Five hundred sixty-two proteins were differentially

Table 1. Proteins With Altered N-Terminal Acetylation in Wildtype and NAA15 Mutant iPSCs*

Accession	Description	Nt-acetylation percentage				Protein levels (fold change)	
		+/+	+/-	-/-	+/R276W	+/- / +/+	-/- / +/+
Q9UNS2	COPS3	99.4	99.9	83.6	99.6	1.87	2.00
Q8TDD1	ATP-dependent RNA helicase (DDX54)	30.8	0	0.7	29.6	2.00	2.46
O60869	EDF1	93	81.6	99	97.5	0.38	0.31
Q9NZM5	Ribosome biogenesis protein (NOP53)	70.6	0	0	84	2.83	4.92
P16401	Histone H1.5	96.7	92.8	37.1	98.2	0.20	0.22
P16403	Histone H1.2	99.5	98.4	50.6	99.5	0.27	0.29
P16402	Histone H1.3	99.6	99.5	62	99.6	0.27	0.29
P10412	Histone H1.4	97.6	93.7	30.9	98.4	0.27	0.29
O95139	NDUFB6	57.5	0	7.4	0	0.33	0.27
Q86U42	PABPN1	99.8	99.3	67.6	0	2.30	2.30
Q15102	PAFAH1B3	99.7	99.6	84.7	99.4	3.48	4.29
Q96BP3	PPWD1	99.8	0	85.6	98.8	0.33	0.13
Q9UN37	VPS4A	98.6	98.6	79.4	99.4	1.00	0.27
Q9HB71	CACYBP	99.4	99.6	67.9	100	.81	.93
P14854	COX6B1	99.2	99.2	67.3	99.2	1.62	1.62
Q02790	FKBP4	14.3	11.9	3.3	14.3	0.81	3.43
Q92616	eIF-2- α kinase activator GCN1	62	54.2	7.3	0	1.41	1.15
O76003	GLRX3	98.2	0	85.3	94	1.15	1.07
Q00839	HNRNPU	99	98.7	79.9	96.4	1.52	1.62
Q8IXQ5	KLHL7	96.5	94	48.7	98.3	0.76	0.81
Q96AG4	LRRC59	60	52.3	7.9	70.7	1.41	1.62
P62937	PPIA	34.3	31.7	6.4	29	1.15	0.93
P62913	RPL11	99.6	99.3	77.9	99.6	1.00	0.93
P40429	RPL13A	95.4	92	3.5	95.3	0.76	0.76
P25398	RPS12	98	99	82.4	92.9	1.23	1.23
Q8NI27	THOC2	99.7	50.4	0	0	1.00	1.07
Q9Y5J9	TIMM8B	95.5	96	82.7	0	1.62	1.52
O94826	TOMM70A	98.7	98	61	98.4	1.41	1.62
Q04323	UBXN1	99.1	96.7	41	99.3	0.81	0.81
P31946	YWHAB	95.3	93.7	50.9	96.6	1.32	1.41
Q9NXW9	ALKBH4	97.5	44.6	0	0	ND†	ND†
Q9NRG0	CHRC1	99.4	88.3	99.7	99.1	ND†	ND†
Q9Y241	HIG1A	98.9	99.4	87.3	99.3	ND†	ND†
P17096	HMGA1	99.5	99.5	88.8	99.6	ND†	ND†

ALKBH4 indicates α -ketoglutarate-dependent dioxygenase; CACYBP, calcyclin-binding protein; CHRC1, chromatin accessibility complex protein 1; COPS3, COP9 signalosome complex subunit 3; COX6B1, cytochrome c oxidase subunit 6B1; EDF1, endothelial differentiation-related factor 1; FKBP4, peptidyl-prolyl cis-trans isomerase; GLRX3, glutaredoxin 3; HIG1A, HIG1 domain family member 1A, mitochondrial; HMGA1, high mobility group protein HMG-I/HMG-Y; HNRNPU, heterogeneous nuclear ribonucleoprotein U; iPSC, induced pluripotent stem cell; KLHL7, Kelch-like protein 7; LRRC59, leucine-rich repeat-containing protein 59; NDUFB6, NADH dehydrogenase (ubiquinone) 1 β subcomplex subunit 6; PABPN1, polyadenylate-binding protein 2; PAFAH1B3, platelet-activating factor acetylhydrolase IB subunit γ ; PPIA, peptidyl-prolyl cis-trans isomerase A; PPWD1, peptidyl-prolyl isomerase domain and WD repeat-containing protein 1; RPL11, 60S ribosomal protein L11; RPL13A, 60S ribosomal protein L13a; RPS12, 40S ribosomal protein S12; THOC2, THO complex subunit 2; TIMM8B, mitochondrial import inner membrane translocase subunit; TOMM70A, mitochondrial import receptor subunit; UBXN1, UBX domain-containing protein 1; VPS4A, vacuolar protein sorting-associated protein 4; and YWHAB, 14-3-3 protein beta/alpha.

*Altered acetylation levels= $>10\%$ deviation.

†Protein levels could not be determined or quantified.

expressed in both *NAA15*^{+/-} and *NAA15*^{-/-} iPSCs compared with WT iPSCs and 505 proteins in *NAA15*^{-/-} iPSCs but not *NAA15*^{+/-} iPSCs (Figure 4B, Figure VII and Tables VIII through X in the [Data Supplement](#)). More than 60% of differentially expressed proteins

had a NataA-target residue at position 2 of the mature protein (Table XI in the [Data Supplement](#)). NataA-target residues, alanine and serine, were frequently observed at position 2. Similar frequencies are seen in proteins with no expression changes (Table XI in the [Data](#)

Table 2. Second and Third Amino Acid Identities of Peptides With Altered Nt-Acetylation in NAA15 Mutant iPSCs

Amino acid residue	No. of peptides		
	-/-	+/-	+/R276W
AA	10	6	5
AD	0	1	0
AE	5	1	1
AQ	2	0	1
AS	2	0	0
SE	5	0	0
SG	1	0	0
SS	1	0	0
ST	1	0	0
TA	1	0	0
TG	1	1	1
TK	1	0	1
TM	1	0	0
TT	1	0	0
VN	1	0	0

A indicates alanine; D, aspartic acid; E, glutamic acid; G, glycine; iPSC, induced pluripotent stem cell; K, lysine; M, methionine; N, asparagine, Q, glutamine; S, serine; T, threonine; and V, valine.

Supplement). Despite the large numbers of differentially expressed proteins, there were very few, if any, significant differences in mRNA levels, as assessed by RNAseq analysis (Tables III and IV in the Data Supplement).

Among differentially expressed proteins identified in *NAA15*^{+/-} iPSCs and *NAA15*^{-/-} iPSCs, the levels of HYPK, a component of the NatA complex that interacts with NAA15, were significantly reduced (Figure 1C).^{14-17,22} A total of 29 out of 54 known interactors of HYPK were detected in the WT iPSCs.⁴⁷ Although HYPK was decreased in MS measurements, there was no enrichment of HYPK interacting proteins that were differentially expressed. Only 6 of 29 known HYPK interacting proteins were decreased in *NAA15*-mutant iPSCs ($P=0.3$; Tables IX and X in the Data Supplement).

To test the hypothesis that differentially expressed proteins shared a common function, the 562 proteins differentially expressed in both *NAA15*^{+/-} and *NAA15*^{-/-} iPSCs were analyzed by gene ontology analysis using clusterProfiler (implemented in R; Methods in the Data Supplement).²⁸ Of the 3 gene ontology enrichment processes that were performed, we found no enrichment after Bonferroni correction for proteins with shared biological function or molecular processes; however, 41 ribosomal (-associated) proteins with altered expression levels were observed ($P=5\times 10^{-6}$), Table XII in the Data Supplement, Figure 4C). These proteins included the catalytic subunit of the NatA complex, NAA10, and ribosomal proteins of the 60S large and 40S small ribosome subunits that function in protein synthesis

(Figure 1B, Table XII in the Data Supplement, and Figure 4D and 4E).⁴⁸⁻⁵²

Ribosomal Protein Deficiency Due to NAA15 Haploinsufficiency

Twenty-nine ribosomal proteins of the 84 proteins that comprise 60S or 40S ribosomal subunit^{53,54} were affected in *NAA15*^{+/-} and *NAA15*^{-/-} iPSCs; eleven 60S large ribosomal proteins and 6 small ribosomal proteins were affected in both *NAA15*^{+/-} and *NAA15*^{-/-} iPSCs (Tables IX and X in the Data Supplement, Figure 4D). Twelve ribosomal proteins were differentially expressed in *NAA15*^{-/-} iPSCs but not in *NAA15*^{+/-} iPSCs (Tables IX and X in the Data Supplement).

NAA15 facilitates binding of the NatA complex to the ribosome.⁵⁵⁻⁵⁸ The general docking site for NatA resides at the ribosomal exit tunnel near large ribosomal unit RPL25 (L23A), a general docking platform for various factors that are transiently associated with ribosomes.^{55,57,59-61} Dysregulated ribosomal proteins observed in both *NAA15*^{+/-} and *NAA15*^{-/-} iPSCs clustered near the NatA docking site (Figure 5A through 5C). Affected small ribosomal subunits (RPS18, RPS25, RPS16, RPS19, RPS20) were clustered at the head of the small ribosomal subunit⁵³ (Figure 5C). Large ribosomal units⁵³ (RPL5 [ribosomal protein L5], RPL13, RPL15, RPL19, RPL30, RPL31, RPL35, RPL23A, RPL39) with low protein levels were clustered at the exit tunnel of the ribosome near the NAA15/NatA docking site (Figure 5B).

Fetal Heart Expression and Association With CHD of Proteins Perturbed in NAA15-Haploinsufficient iPSCs

Because extensive protein expression studies of human and mouse fetal heart are not available, we assessed expression of the RNAs encoding these proteins in the mouse and human fetal heart⁶²; $\approx 50\%$ of the 562 proteins are expressed in the mouse and human fetal heart (unpublished). Of these 562 proteins, 4 (DHCR7 [7-dehydrocholesterol reductase], MAP2K2 [mitogen-activated protein kinase kinase 2], NSD1 [nuclear receptor binding SET domain protein 1], and RPL5; Table XIII in the Data Supplement) are encoded by genes known to cause autosomal dominant CHD (Table XIII in the Data Supplement). RNA encoding all 4 of these proteins are found in multiple cell types in the human fetal heart (Figure VIII in the Data Supplement).

DISCUSSION

Exome sequence analyses of 4511 CHD subjects with extra-cardiac phenotypes identified 20 subjects with rare




Figure 4. Proteins differentially expressed in *NAA15*^{+/-} and *NAA15*^{-/-} induced pluripotent stem cells (iPSCs).

A, Scatterplot displays log₂ fold changes of differentially expressed proteins in *NAA15*^{+/-} and *NAA15*^{-/-} iPSCs compared with wildtype (WT) iPSCs. Approximately 1200 proteins are differentially expressed, 9 and 3 proteins of which have reduced Nt-acetylation in *NAA15*^{-/-} iPSCs and *NAA15*^{+/-} iPSCs, respectively. Data was collected from 2 independent undifferentiated iPSC cell lines for each *NAA15* (N-alpha-acetyltransferase 15) mutant genotype and at least 3 technical replicates for each sample. **B**, Comparison of differentially expressed proteins in *NAA15*^{-/-} and *NAA15*^{+/-} iPSCs. Differential expression was considered for log₂ fold change [1]. Identified proteins: 5196, quantified proteins: 3911 proteins detected by mass spectrometry (**C**) gene ontology (GO) enrichment of differentially expressed proteins in both *NAA15*^{-/-} and *NAA15*^{+/-} iPSCs. A total of 41 proteins are localized to the ribosome. Raw *P* value presented in data table. **D**, Bar graph represents log₂ fold change of ribosomal proteins that are differentially expressed in both *NAA15*^{-/-} and *NAA15*^{+/-} iPSCs.

inherited or de novo variants that are predicted to perturb *NAA15* (Table I and Figure I in the [Data Supplement](#), Figure 1A). Similar *NAA15* variants occur in patients with neurological abnormalities.⁵⁷ We explored the consequences of *NAA15* variants using human iPSCs by both transcriptome (RNAseq) and proteomic analyses (Figure 2; Figure II and Tables III, IV, VIII, IX, and X in the [Data Supplement](#)). *NAA15*^{+/-} cells had ~50% of normal levels but like *NAA15*^{+R276W} iPSCs, these differentiated into cardiomyocytes. *NAA15*^{+/-} iPSC-CMs displayed normal unloaded contractility, but impaired contractility when loaded (ie, working against resistance; Figure V in the [Data Supplement](#)). *NAA15*^{-/-} iPSCs produced no *NAA15* and like yeast cells lacking *NAA15*, grew slowly (Figure 2D).¹⁹ *NAA15*-deficiency had minimal effect on the transcriptome but significantly altered the proteome consistent with its role in protein modification.

Because *NAA15* is a component of the NatA complex, we assessed the level of N-terminal protein acetylation in iPSCs carrying *NAA15* variants using positional proteomics. Approximately 650 proteins with N-terminal sequences that were predicted to be NatA targets could be assessed. Only 32 and 9 proteins had altered

Nt-acetylation in *NAA15* null and haploinsufficient cells, respectively. By contrast, levels of 562 proteins were altered in both *NAA15*-null and *NAA15*-haploinsufficient cells suggesting a possible role for *NAA15* and NatA in translation efficiency and protein stability in addition to Nt-acetylation. If *NAA15* was the only available ribosome anchor for *NAA10* and the NatA complex in human cells as it is in yeast cells,^{8,55,58} *NAA15* null cells should present with a complete lack of Nt-acetylation of all NatA substrates. The explanation for the partial effect observed may be due to the presence of the *NAA15* paralogue *NAA16* in human cells; however, the low expression of *NAA16* in iPSCs suggests the need for additional studies to measure whether the paralogue to *NAA15* had any effect on N-terminal acetylation. It has been reported that *NAA16*-*NAA10* complexes may perform NatA-type Nt-acetylation in human cells and partially act as a backup system for the *NAA15*-*NAA10* NatA complex.⁶³

The levels of 18 of the 81 identified ribosomal proteins were altered in *NAA15*-haploinsufficient cells. *NAA15* anchors the NatA complex to the ribosomal large subunit via RPL25 (L23A).^{55-58,64} Consistent with this model, some of these affected proteins clustered




Figure 5. Ribosomal proteins of the 40S small and 60S large subunits affected in *NAA15* (N-alpha-acetyltransferase 15)-mutant iPSCs.

A, Graphical representation of the human 80S ribosomes with affected 40S small and 60S large subunits in both *NAA15*^{-/-} and *NAA15*^{+/-} iPSCs. Ribosomal proteins down in expression highlighted in dark blue (\log_2 fold change < -2) and light blue ($-2 < \log_2$ fold change > -1). NatA (N-terminal acetyltransferase) Docking site is highlighted in yellow. **B**, Diagram showing location of affected 60S large subunits and **(C)** 40S small subunits. Large ribosomal proteins are clustered and located near the NatA docking site. Small ribosomal proteins affected in their expression clustered together.

near the NAA15/NatA docking site. Presumably, NAA15 binding to one or more of these proteins⁵⁶ protects them from subsequent degradation either during ribosome assembly or subsequent ribosomal activity. Previous studies have demonstrated that ribosomal subunit deficiency leads to a variety of pathological states.^{48,50,51,65} Damaging human variants in ribosomal subunits RPS19, RPL5,⁴ and RPL35A have been identified in patients with CHD⁴ (PCGC consortium data not shown) and also contribute to Diamond-Blackfan anemia,^{50,66,67} a disorder that is accompanied by CHD in 30% of patients.⁶⁸

Among differentially expressed proteins in NAA15 haploinsufficient cells, 4 (DHCR7, MAP2K2, NSD1, and

RPL5) are encoded by known CHD genes (Table XIII and Figure VIII in the [Data Supplement](#)) and are most likely responsible for NAA15-haploinsufficient mediated CHD.^{4,69-71} As the precise mechanisms by which each haploinsufficiency of each of these genes is defined, we anticipate the mechanism(s) will be shared by NAA15 haploinsufficient patients.

Exome analyses of CHD probands also identified 16 *NAA15* missense variants, including R276W, a variant of uncertain significance. iPSCs carrying the *NAA15* R276W variant had eight proteins with altered Nt-acetylation, of which 4 had altered Nt-acetylation in NAA15-haploinsufficient cells. These data suggest that the

R276W variant likely impairs NAA15 function, and consequently NatA function, and like heterozygous LoF variants contributes to CHD. Future studies of protein levels in genetically engineered iPSCs carrying other *NAA15* variants found in CHD probands, will help identify those variants contributing to cardiac abnormalities and those variants that are likely benign.

In this study, we use genetically engineered iPSC models to recapitulate *NAA15* LoF and missense variants discovered in CHD patients. We observe that variants in *NAA15* causing *NAA15* haploinsufficiency or deficiency result in either a reduction or complete depletion of NAA15 and NatA protein levels. We find that aberrant protein expression of NAA15 alters Nt-acetylation of a small number of proteins. Most importantly, a reduction of the NAA15 protein interrupts its interaction with the ribosome. The failed interaction causes ribosomal deficiency and mis-expression of a large number of proteins most likely involved in heart development. Protein expression changes are possibly due to obstructed ribosomal machinery and defects in protein synthesis. One or more proteins affected in both *NAA15*-mutant iPSCs have been documented as a cause of congenital heart defects and are likely candidates required for normal cardiac developmental processes.

ARTICLE INFORMATION

Received April 10, 2020; revision received February 3, 2021; accepted February 8, 2021.

Affiliations

Genetics (T.W., W.T., S.M., G.V., M.Y.J., J.A.L.W., A.H., J.G., Y.K., A.P., J.H., C.C.B., S.R.D., C.S., J.G.S.) and Howard Hughes Medical Institute (A.H., C.S.), Harvard Medical School. Division of Newborn Medicine, Boston Children's Hospital (S.M.). VIB Center for Medical Biotechnology, B-9000 Ghent, Belgium (F.I., D.V.H., E.T., K.G.). VIB Proteomics Core, B-9000 Ghent, Belgium (F.I., D.V.H., E.T.). Biomolecular Medicine (F.I., D.V.H., E.T., K.G.) and Biochemistry and Microbiology (P.V.D.), Ghent University, B-9000 Ghent, Belgium. University of Sao Paulo (G.V.). Biomedical Engineering, Boston University, MA (K.Z., C.S.C.). The Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA (K.Z., C.S.C.). Medicine, Brigham and Women's Hospital (A.H., C.S.). Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York (B.D.G.). Pediatrics and Medicine, Columbia University Medical Center, New York (W.K.C.). Cardiology, Children's Hospital of Philadelphia, Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia (E.G.). Pediatrics, University of Rochester Medical Center (G.A.P.). Genetics, Yale University School of Medicine, New Haven (R.P.L., M.B.). Laboratory of Human Genetics and Genomics, Rockefeller University, New York (R.P.L.). Pediatrics, Yale University School of Medicine, New Haven (M.B.). Molecular Medicine Program, University of Utah, Salt Lake City (H.J.Y.). Gladstone Institutes, San Francisco, CA (B.G.B.). Division of Cardiovascular Medicine, Brigham and Women's Hospital (Y.K.). Biomedicine (S.V., T.A.) and Biological Sciences (S.V., T.A.), University of Bergen, N-5020 Bergen, Norway. Donnelly Centre for Cellular and Biomolecular Research, Toronto, Canada (S.V.). Surgery, Haukeland University Hospital, N-5021 Bergen, Norway (T.A.).

Acknowledgments

We would like to thank Paula Montero Llopis of the MicRoN (Microscopy Resources On the North Quad) core for her support and assistance, specifically for collecting images in Figure 2. We appreciate the study participants and their families, without whom this work would not have been possible.

Sources of Funding

We gratefully acknowledge the National Heart, Lung, and Blood Institute Pediatrics Cardiac Genomics Consortium (PCGC) and Cardiovascular Develop-

ment Consortium (CVDC) investigators (B.D. Gelb, W.K. Chung, E. Goldmuntz, G.A. Porter, R.P. Lifton, M. Brueckner, H.J. Yost, B.G. Bruneau, C.E. Seidman, J.G. Seidman) for their support and expertise in cardiovascular development. Funding support for this study was provided by grants to the PCGC and CVDC by the US National Heart Lung and Blood Institute (UM1 HL098123 [B.D. Gelb], U01 HL098153 [EG], UM1HL098179 [B.G. Bruneau], R01 HL151257 [C.E. Seidman], 1UM1HL098166 [J.G. Seidman]), SFARI and the JPB Foundation (W.K. Chung), Harvard Medical School Diversity and Inclusion Dean's Postdoctoral Fellowship (T. Ward), Stanley J. Sarnoff Cardiovascular Research Foundation (W. Tai), HHMI Medical Research Fellowship (M.Y. Jang), FAPESP number 19/11921-1 and 18/13706-0 (G. Venturini), K. Zhang acknowledges fellowship support from the American Heart Association, award number 17PRE33660967, John S. Ladue Memorial Fellowship at Harvard Medical School (Y. Kim), S. Varland and T. Arnesen were funded by the Research Council of Norway through a FRIPRO mobility grant 261981, which is cofunded by the European Union's Seventh Framework Programme under Marie Curie grant agreement no 608695, the Research Council of Norway (project 249843), the Norwegian Health Authorities of Western Norway (project F-12540), and the Norwegian Cancer Society. Funding was supported by the Engineering Research Centers Program of the National Science Foundation, no.EEC-1647837 (C.S. Chen). K. Gevaert acknowledges support from The Research Foundation—Flanders (FWO), project number G008018N. Funding was supported by the Howard Hughes Medical Institute (C.E. Seidman), and Fondation Leducq 16 CVD 03 (J.G. Seidman).

Disclosures

None.

Supplemental Materials

Expanded Online Materials and Methods
Online Figures I–VIII
Online Movies I–VIII
Data Set of Online Tables I–XIII
References 72–76

REFERENCES

- van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2011;58:2241–2247. doi: 10.1016/j.jacc.2011.08.025
- Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, DePalma SR, McKean D, Wakimoto H, Gorham J, et al. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. *Science*. 2015;350:1262–1266. doi: 10.1126/science.aac9396
- Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Romano-Adesman A, Bjornson RD, Breitbart RE, Brown KK, et al. De novo mutations in histone-modifying genes in congenital heart disease. *Nature*. 2013;498:220–223. doi: 10.1038/nature12141
- Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, Zeng X, Qi H, Chang W, Sierant MC, et al. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. *Nat Genet*. 2017;49:1593–1601. doi: 10.1038/ng.3970
- Cheng H, Dharmadhikari AV, Varland S, Ma N, Domingo D, Kleyner R, Rope AF, Yoon M, Stray-Pedersen A, Posey JE, et al. Truncating variants in NAA15 are associated with variable levels of intellectual disability, autism spectrum disorder, and congenital anomalies. *Am J Hum Genet*. 2018;102:985–994. doi: 10.1016/j.ajhg.2018.03.004
- Guo H, Wang T, Wu H, Long M, Coe BP, Li H, Xun G, Ou J, Chen B, Duan G, et al. Inherited and multiple de novo mutations in autism/developmental delay risk genes suggest a multifactorial model. *Mol Autism*. 2018;9:64. doi: 10.1186/s13229-018-0247-z
- Zhao JJ, Halvardson J, Zander CS, Zaghlool A, Georgii-Hemming P, Månsson E, Brandberg G, Sävmarker HE, Frykholm C, Kuchinskaya E, et al. Exome sequencing reveals NAA15 and PUF60 as candidate genes associated with intellectual disability. *Am J Med Genet B Neuropsychiatr Genet*. 2018;177:10–20. doi: 10.1002/ajmg.b.32574
- Arnesen T, Van Damme P, Polevoda B, Helsen K, Evjenth R, Colaert N, Varhaug JE, Vandekerckhove J, Lillehaug JR, Sherman F, et al. Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. *Proc Natl Acad Sci U S A*. 2009;106:8157–8162. doi: 10.1073/pnas.0901931106

9. Drazic A, Myklebust LM, Ree R, Arnesen T. The world of protein acetylation. *Biochim Biophys Acta*. 2016;1864:1372–1401. doi: 10.1016/j.bbapap.2016.06.007
10. Aksnes H, Drazic A, Marie M, Arnesen T. First things first: vital protein marks by N-terminal acetyltransferases. *Trends Biochem Sci*. 2016;41:746–760. doi: 10.1016/j.tibs.2016.07.005
11. Aksnes H, Ree R, Arnesen T. Co-translational, post-translational, and non-catalytic roles of N-terminal acetyltransferases. *Mol Cell*. 2019;73:1097–1114. doi: 10.1016/j.molcel.2019.02.007
12. Frottin F, Martinez A, Peynot P, Mitra S, Holz RC, Giglione C, Meinel T. The proteomics of N-terminal methionine cleavage. *Mol Cell Proteomics*. 2006;5:2336–2349. doi: 10.1074/mcp.M600225-MCP200
13. Arnold RJ, Polevoda B, Reilly JP, Sherman F. The action of N-terminal acetyltransferases on yeast ribosomal proteins. *J Biol Chem*. 1999;274:37035–37040. doi: 10.1074/jbc.274.52.37035
14. Choudhury KR, Raychaudhuri S, Bhattacharyya NP. Identification of HYPK-interacting proteins reveals involvement of HYPK in regulating cell growth, cell cycle, unfolded protein response and cell death. *PLoS One*. 2012;7:e51415. doi: 10.1371/journal.pone.0051415
15. Gottlieb L, Marmorstein R. Structure of human NatA and its regulation by the huntingtin interacting protein HYPK. *Structure*. 2018;26:925–935.e8. doi: 10.1016/j.str.2018.04.003
16. Raychaudhuri S, Sinha M, Mukhopadhyay D, Bhattacharyya NP. HYPK, a Huntingtin interacting protein, reduces aggregates and apoptosis induced by N-terminal Huntingtin with 40 glutamines in Neuro2a cells and exhibits chaperone-like activity. *Hum Mol Genet*. 2008;17:240–255. doi: 10.1093/hmg/ddm301
17. Weyer FA, Gumiero A, Lapouge K, Bange G, Kopp J, Sinning I. Structural basis of HypK regulating N-terminal acetylation by the NatA complex. *Nat Commun*. 2017;8:15726. doi: 10.1038/ncomms15726
18. Deng S, Magin RS, Wei X, Pan B, Petersson EJ, Marmorstein R. Structure and mechanism of acetylation by the N-terminal dual enzyme NatA/Naa50 complex. *Structure*. 2019;27:1057–1070.e4. doi: 10.1016/j.str.2019.04.014
19. Mullen JR, Kayne PS, Moerschell RP, Tsunawasa S, Gribskov M, Colavito-Shepanski M, Grunstein M, Sherman F, Sternglanz R. Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. *EMBO J*. 1989;8:2067–2075.
20. Arnesen T, Anderson D, Baldersheim C, Lanotte M, Varhaug JE, Lillehaug JR. Identification and characterization of the human ARD1–NATH protein acetyltransferase complex. 2005;386:433–443.
21. Liszczak G, Goldberg JM, Foy H, Petersson EJ, Arnesen T, Marmorstein R. Molecular basis for N-terminal acetylation by the heterodimeric NatA complex. *Nat Struct Mol Biol*. 2013;20:1098–1105. doi: 10.1038/nsmb.2636
22. Arnesen T, Starheim KK, Van Damme P, Evjenth R, Dinh H, Betts MJ, Rynningen A, Vandekerckhove J, Gevaert K, Anderson D. The chaperone-like protein HYPK acts together with NatA in cotranslational N-terminal acetylation and prevention of Huntingtin aggregation. *Mol Cell Biol*. 2010;30:1898–1909. doi: 10.1128/MCB.01199-09
23. Myklebust LM, Van Damme P, Støve SI, Dörfel MJ, Abboud A, Kalvik TV, Grauffel C, Jonckheere V, Wu Y, Swensen J, et al. Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects. *Hum Mol Genet*. 2015;24:1956–1976. doi: 10.1093/hmg/ddu611
24. Fluge Ø, Bruland O, Akslen LA, Varhaug JE, Lillehaug JR. NATH, a novel gene overexpressed in papillary thyroid carcinomas. *Oncogene*. 2002;21:5056–5068. doi: 10.1038/sj.onc.1205687
25. Gelb B, Brueckner M, Chung W, Goldmuntz E, Kaltman J, Kaski JP, Kim R, Kline J, Mercer-Rosa L, Porter G, et al; Pediatric Cardiac Genomics Consortium. The congenital heart disease genetic network study. *Circulation Research*. 2013;112:698–706.
26. Ohye RG, Sleeper LA, Mahony L, Newburger JW, Pearson GD, Lu M, Goldberg CS, Tabbutt S, Frommelt PC, Ghanayem NS, et al; Pediatric Heart Network Investigators. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. *N Engl J Med*. 2010;362:1980–1992. doi: 10.1056/NEJMoa0912461
27. Sharma A, Toepfer CN, Ward T, Wasson L, Agarwal R, Conner DA, Hu JH, Seidman CE. CRISPR/Cas9-mediated fluorescent tagging of endogenous proteins in human pluripotent stem cells. *Current protocols in human genetics*. 2018;96:21.11.1–21.11.20.
28. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS*. 2012;16:284–287. doi: 10.1089/omi.2011.0118
29. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. *Proc Natl Acad Sci USA*. 2001;98:5116–5121. doi: 10.1073/pnas.091062498
30. Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, Raval KK, Zhang J, Kamp TJ, Palecek SP. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. *Proc Natl Acad Sci USA*. 2012;109:E1848–E1857. doi: 10.1073/pnas.1200250109
31. Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X, Hsiao C, Kamp TJ, Palecek SP. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. *Nat Protoc*. 2013;8:162–175. doi: 10.1038/nprot.2012.150
32. Arnesen T, Gromyko D, Pendino F, Rynningen A, Varhaug JE, Lillehaug JR. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. *Oncogene*. 2006;25:4350–4360. doi: 10.1038/sj.onc.1209469
33. Gromyko D, Arnesen T, Rynningen A, Varhaug JE, Lillehaug JR. Depletion of the human Nα-terminal acetyltransferase A induces p53-dependent apoptosis and p53-independent growth inhibition. *Int J Cancer*. 2010;127:2777–2789. doi: 10.1002/ijc.25275
34. Kalvik TV, Arnesen T. Protein N-terminal acetyltransferases in cancer. *Oncogene*. 2013;32:269–276. doi: 10.1038/onc.2012.82
35. Toepfer CN, Sharma A, Cicconet M, Garfinkel AC, Mücke M, Neyazi M, Willcox JAL, Agarwal R, Schmid M, Rao J, et al. SarcTrack. *Circ Res*. 2019;124:1172–1183. doi: 10.1161/CIRCRESAHA.118.314505
36. Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, Gorham J, Yang L, Schafer S, Sheng CC, et al. HEART DISEASE. Titin mutations in iPSC cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. *Science*. 2015;349:982–986. doi: 10.1126/science.aaa5458
37. Legant WR, Pathak A, Yang MT, Deshpande VS, McMeeking RM, Chen CS. Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues. *Proc Natl Acad Sci USA*. 2009;106:10097–10102. doi: 10.1073/pnas.0900174106
38. Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J. Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. *Nat Biotechnol*. 2003;21:566–569. doi: 10.1038/nbt810
39. Staes A, Impens F, Van Damme P, Ruttens B, Goethals M, Demol H, Timmerman E, Vandekerckhove J, Gevaert K. Selecting protein N-terminal peptides by combined fractional diagonal chromatography. *Nat Protoc*. 2011;6:1130–1141. doi: 10.1038/nprot.2011.355
40. Van Damme P, Van Damme J, Demol H, Staes A, Vandekerckhove J, Gevaert K. A review of COFRADIC techniques targeting protein N-terminal acetylation. *BMC Proc*. 2009;3(suppl 6):S6. doi: 10.1186/1753-6561-3-S6-S6
41. UniProt Consortium. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res*. 2019;47:D506–D515.
42. Yan J, Walz K, Nakamura H, Carattini-Rivera S, Zhao Q, Vogel H, Wei N, Justice MJ, Bradley A, Lupski JR. COP9 signalosome subunit 3 is essential for maintenance of cell proliferation in the mouse embryonic epiblast. *Mol Cell Biol*. 2003;23:6798–6808. doi: 10.1128/mcb.23.19.6798-6808.2003
43. Zhang Y, Cooke M, Panjwani S, Cao K, Krauth B, Ho PY, Medrzycki M, Berhe DT, Pan C, McDevitt TC, et al. Histone h1 depletion impairs embryonic stem cell differentiation. *PLoS Genet*. 2012;8:e1002691. doi: 10.1371/journal.pgen.1002691
44. Mangé A, Coyaud E, Desmetz C, Laurent E, Béganton B, Coopman P, Raught B, Solassol J. FKBP4 connects mTORC2 and PI3K to activate the PDK1/Akt-dependent cell proliferation signaling in breast cancer. *Theranostics*. 2019;9:7003–7015. doi: 10.7150/thno.35561
45. Teng T, Mercer CA, Hexley P, Thomas G, Fumagalli S. Loss of tumor suppressor RPL5/RPL11 does not induce cell cycle arrest but impedes proliferation due to reduced ribosome content and translation capacity. *Mol Cell Biol*. 2013;33:4660–4671. doi: 10.1128/MCB.01174-13
46. Bhattacharjee RB, Bag J. Depletion of nuclear poly(A) binding protein PABPN1 produces a compensatory response by cytoplasmic PABP4 and PABP5 in cultured human cells. *PLoS One*. 2012;7:e53036. doi: 10.1371/journal.pone.0053036
47. Choudhury KR, Bucha S, Baksi S, Mukhopadhyay D, Bhattacharyya NP. Chaperone-like protein HYPK and its interacting partners augment autophagy. *Eur J Cell Biol*. 2016;95:182–194. doi: 10.1016/j.jecb.2016.03.003
48. Cheng Z, Mugler CF, Keskin A, Hodapp S, Chan LY, Weis K, Mertins P, Regev A, Jovanovic M, Brar GA. Small and large ribosomal subunit deficiencies lead to distinct gene expression signatures that reflect cellular growth rate. *Mol Cell*. 2019;73:36–47.e10. doi: 10.1016/j.molcel.2018.10.032
49. Gregory B, Rahman N, Bommakanti A, Shamsuzzaman M, Thapa M, Lescuré A, Zengel JM, Lindahl L. The small and large ribosomal subunits depend on each other for stability and accumulation. *Life Sci Alliance*. 2019;2:e201800150.

50. Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. *Blood*. 2010;115:3196–3205. doi: 10.1182/blood-2009-10-178129
51. Peisker K, Braun D, Wölfle T, Hentschel J, Fünfschilling U, Fischer G, Sickmann A, Rospert S. Ribosome-associated complex binds to ribosomes in close proximity of Rpl31 at the exit of the polypeptide tunnel in yeast. *Mol Biol Cell*. 2008;19:5279–5288. doi: 10.1091/mbc.e08-06-0661
52. Steffen KK, McCormick MA, Pham KM, MacKay VL, Delaney JR, Murakami CJ, Kaeberlein M, Kennedy BK. Ribosome deficiency protects against ER stress in *Saccharomyces cerevisiae*. *Genetics*. 2012;191:107–118. doi: 10.1534/genetics.111.136549
53. Khatter H, Myasnikov AG, Natchiar SK, Klaholz BP. Structure of the human 80S ribosome. *Nature*. 2015;520:640–645. doi: 10.1038/nature14427
54. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. *J Mol Graph*. 1996;14:33–38, 27. doi: 10.1016/0263-7855(96)00018-5
55. Gautschi M, Just S, Mun A, Ross S, Rücknagel P, Dubaquié Y, Ehrenhofer-Murray A, Rospert S. The yeast N(alpha)-acetyltransferase NatA is quantitatively anchored to the ribosome and interacts with nascent polypeptides. *Mol Cell Biol*. 2003;23:7403–7414. doi: 10.1128/mcb.23.20.7403-7414.2003
56. Knorr AG, Schmidt C, Tesina P, Berninghausen O, Becker T, Beatrix B, Beckmann R. Ribosome-NatA architecture reveals that rRNA expansion segments coordinate N-terminal acetylation. *Nat Struct Mol Biol*. 2019;26:35–39. doi: 10.1038/s41594-018-0165-y
57. Polevoda B, Brown S, Cardillo TS, Rigby S, Sherman F. Yeast N(alpha)-terminal acetyltransferases are associated with ribosomes. *J Cell Biochem*. 2008;103:492–508. doi: 10.1002/jcb.21418
58. Varland S, Arnesen T. Investigating the functionality of a ribosome-binding mutant of NAA15 using *Saccharomyces cerevisiae*. *BMC Res Notes*. 2018;11:404. doi: 10.1186/s13104-018-3513-4
59. Kramer G, Boehringer D, Ban N, Bukau B. The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins. *Nat Struct Mol Biol*. 2009;16:589–597. doi: 10.1038/nsmb.1614
60. Kramer G, Rauch T, Rist W, Vorderwülbecke S, Patzelt H, Schulze-Specking A, Ban N, Deuerling E, Bukau B. L23 protein functions as a chaperone docking site on the ribosome. *Nature*. 2002;419:171–174. doi: 10.1038/nature01047
61. Wilson DN, Nierhaus KH. Ribosomal proteins in the spotlight. *Crit Rev Biochem Mol Biol*. 2005;40:243–267. doi: 10.1080/10409230500256523
62. Cui Y, Zheng Y, Liu X, Yan L, Fan X, Yong J, Hu Y, Dong J, Li Q, Wu X, et al. Single-cell transcriptome analysis maps the developmental track of the human heart. *Cell Rep*. 2019;26:1934–1950.e5. doi: 10.1016/j.celrep.2019.01.079
63. Arnesen T, Gromyko D, Kagabo D, Betts MJ, Starheim KK, Varhaug JE, Anderson D, Lillehaug JR. A novel human NatA Nalpha-terminal acetyltransferase complex: hNaa16p-hNaa10p (hNat2-hArd1). *BMC Biochem*. 2009;10:15. doi: 10.1186/1471-2091-10-15
64. Magin RS, Deng S, Zhang H, Cooperman B, Marmorstein R. Probing the interaction between NatA and the ribosome for co-translational protein acetylation. *PLoS One*. 2017;12:e0186278. doi: 10.1371/journal.pone.0186278
65. Warren AJ. Molecular basis of the human ribosomopathy Shwachman-Diamond syndrome. *Adv Biol Regul*. 2018;67:109–127. doi: 10.1016/j.jbior.2017.09.002
66. Farrar JE, Nater M, Caywood E, McDevitt MA, Kowalski J, Takemoto CM, Talbot CC Jr, Meltzer P, Esposito D, Beggs AH, et al. Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. *Blood*. 2008;112:1582–1592. doi: 10.1182/blood-2008-02-140012
67. Gazda HT, Sheen MR, Vlachos A, Choessel V, O'Donohue MF, Schneider H, Darras N, Hasman C, Sieff CA, Newburger PE, et al. Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. *Am J Hum Genet*. 2008;83:769–780. doi: 10.1016/j.ajhg.2008.11.004
68. Vlachos A, Osorio DS, Atsidaftos E, Kang J, Lababidi ML, Seiden HS, Gruber D, Glader BE, Onel K, Farrar JE, et al. Increased prevalence of congenital heart disease in children with Diamond Blackfan anemia suggests unrecognized Diamond Blackfan anemia as a cause of congenital heart disease in the general population: a report of the Diamond Blackfan Anemia Registry. *Circ Genom Precis Med*. 2018;11:e002044. doi: 10.1161/CIRCGENETICS.117.002044
69. Machel L. [Genetic diseases on the Internet: OMIM]. *Ann Dermatol Venereol*. 1998;125:645.
70. Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore. Accessed April 2020. <https://omim.org/>
71. Oyston J. Online Mendelian Inheritance in Man. *Anesthesiology*. 1998;89:811–812. doi: 10.1097/0000542-199809000-00060
72. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR; 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature*. 2015;526:68–74. doi: 10.1038/nature15393
73. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytzky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res*. 2010;20:1297–1303. doi: 10.1101/gr.107524.110
74. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, Jordan T, Shakir K, Roazen D, Thibault J, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Curr Protoc Bioinformatics*. 2013;43:11.10.1–11.10.33. doi: 10.1002/0471250953.bi1110s43
75. Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, Liu X. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. *Hum Mol Genet*. 2015;24:2125–2137. doi: 10.1093/hmg/ddu733
76. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. *Mol Cell Proteomics*. 2014;13:2513–2526. doi: 10.1074/mcp.M113.031591